The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Vebreltinib plus PLB1004 in EGFR-mutated NSCLC with acquired MET amplification or overexpression after failure on EGFR-TKI treatment: A phase Ib/II study.
 
Fei Zhou
No Relationships to Disclose
 
Shengxiang Ren
No Relationships to Disclose
 
Guowei Che
No Relationships to Disclose
 
Chen Zhou
No Relationships to Disclose
 
Xin Zhao
No Relationships to Disclose
 
Jun Zhao
No Relationships to Disclose
 
Yanqiu Zhao
No Relationships to Disclose
 
Jianchun Duan
No Relationships to Disclose
 
Lin Wu
No Relationships to Disclose
 
Yongchang Zhang
No Relationships to Disclose
 
Chengzhi Zhou
No Relationships to Disclose
 
Caicun Zhou
Honoraria - Akeso Biopharma; Amoy Diagnostics; Hengrui Therapeutics; Innovent Biologics; Luye Pharma; QiLu Pharmaceutical; TopAlliance BioSciences Inc
Consulting or Advisory Role - Innovent Biologics; QiLu Pharmaceutical